前往化源商城

Chemical & Pharmaceutical Bulletin 2014-01-01

Contribution of glucose to crystallization of phenytoin in injectable dosage form by dilution with infusion fluids.

Yoshinori Onuki, Naoki Hasegawa, Mayumi Ikegami-Kawai, Takako Suematsu, Satoshi Sakurai, Shunsuke Shirozu, Masayoshi Tsubuki, Yasuko Obata, Kozo Takayama

文献索引:Chem. Pharm. Bull. 62(10) , 989-93, (2014)

全文:HTML全文

摘要

The crystallization of phenytoin occurring after its dilution with infusion fluid is a major concern in the clinical use of injectable phenytoin. To gain further understanding of the crystallization, this study assessed details of the involvement of glucose in this action. For sample preparation, phenytoin crystals were created by diluting the injectable phenytoin with infusion fluids with different glucose concentrations at different temperature, and then the characteristics of the crystallization (e.g., crystal size in the long direction, accumulated amount over 24 h, and crystallization rate constant) were measured. Results of the analysis of variance indicated that the glucose concentration and temperature had significant impacts on the crystallization. The mode of action of the glucose concentration was suggested to be different from that of the incubation temperature. This study also examined the molecular mobility of components (i.e., glucose, propylene glycol, phenytoin) in the admixtures using diffusion NMR techniques. The findings will provide valuable information for the clinical use of injectable phenytoin.

相关化合物

结构式 名称/CAS号 全部文献
重水 结构式 重水
CAS:7789-20-0
氢氧化钠 结构式 氢氧化钠
CAS:1310-73-2
乙腈 结构式 乙腈
CAS:75-05-8
3-乙基-2,4-戊烷二酮 结构式 3-乙基-2,4-戊烷二酮
CAS:1540-34-7
丙二醇 结构式 丙二醇
CAS:57-55-6
D(+)-无水葡萄糖 结构式 D(+)-无水葡萄糖
CAS:50-99-7
苯妥英钠 结构式 苯妥英钠
CAS:630-93-3